Prognostic significance of phosphorylated STAT-1 expression in premenopausal and postmenopausal patients with invasive breast cancer

Histopathology

Volumn 60, Issue 7, 2012, Pages 1125-1132

  Magkou, Christina ^a   Giannopoulou, Ioanna ^b   Theohari, Irene ^b   Fytou, Alexandra ^b   Rafailidis, Petros ^b   Nomikos, Alexandros ^b   Papadimitriou, Christos ^c   Nakopoulou, Lydia ^b  

^a Department of Pathology   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Immunohistochemistry; Invasive breast cancer; Menopause; PSTAT 1; Survival

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; CASPASE 3; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN KINASE B; STAT1 PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHENOTYPE; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CASPASE 3; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM INVASIVENESS; PHOSPHORYLATION; POSTMENOPAUSE; PREMENOPAUSE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; STAT1 TRANSCRIPTION FACTOR;

EID: 84861482411     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04143.x     Document Type: Article

References (31)

1. Eigeliene N, Harkonen P, Erkalla R. Effects of estradiol and medroxyprogesterone acetate on expression of the cell cycle proteins cyclin D1, p21 and p27 in cultured human breast tissues. Cell Cycle 2008; 7; 71-80.
2. Calo V, Migliavacca M, Bazan V et al. STAT proteins: from normal control of cellular events to tumorigenesis. J. Cell. Physiol. 2003; 197; 157-168.
3. Proietti C, Salatino M, Rosemblit C et al. Progestins induce transcriptional activation of Signal Transducer and Activator of Transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells. Mol. Cell. Biol. 2005; 25; 4826-4840.
4. Adamkova L, Soucskova K, Kovarik J. Transcription protein STAT1: biology and relation to cancer. Folia Biol. 2007; 53; 1-6.
5. Silva CM, Shupnik MA. Integration of steroid and growth factor pathways in breast cancer: focus on signal transducers and activators of transcription and their potential role in resistance. Mol. Endocrinol. 2007; 21; 1499-1512.
6. Lin VC, Jin R, Tan PH, Aw SE, Woon CT, Bay BH. Progesterone induces cellular differentiation in MDA-MB-231 breast cancer cells transfected with progesterone receptor complementary DNA. Am. J. Pathol. 2003; 162; 1781-1787.
7. Stephanou A, Latchman DS. Opposing actions of STAT-1 and STAT-3. Growth Factors 2005; 23; 177-182.
8. Paukku K, Silvennoinen O. STATs as critical mediators of signal transduction and transcription: lessons learned from STAT5. Cytokine Growth Factor Rev. 2004; 15; 435-455.
9. Alvaro T, Lejeune M, Camacho FI et al. The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica 2006; 91; 1605-1612.
10. World Health Organization. The World Health Organization histological typing of breast tumors, 2nd edn. Am. J. Clin. Pathol. 2003; 78; 806-816.
11. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res. Treat. 1992; 22; 207-219.
12. Flening ID, Cooper JS, Henson DE et al. eds. AJCC cancer staging manual, 5th edn. Philadelphia, PA: Lippincott-Raven, 1997.
13. Nakopoulou L, Alexandrou P, Stefanaki K, Panayotopoulou E, Lazaris AC, Davaris PS. Immunohistochemical expression of caspase-3 as an adverse indicator of the clinical outcome in human breast cancer. Pathobiology 2001; 69; 266-273.
14. Magkou C, Mylona E, Theohari I et al. An immunohistochemical evaluation of phosphorylated Akt at threonine 308 [pAkt(Thr308)] in invasive breast cancer. In Vivo 2007; 21; 967-972.
15. Sheen-Chen SM, Huang CC, Tang RP, Yang CH, Chou FF, Eng HL. Signal transducer and activator of transcription 1 in breast cancer: analysis with tissue microarray. Anticancer Res. 2007; 27; 2481-2486.
16. Berclaz G, Altermatt HJ, Rohrbach V, Siragusa A, Dreher E, Smith PD. EGFR dependent expression of STAT3 (but not STAT1) in breast cancer. Int. J. Oncol. 2001; 19; 1155-1160.
17. Charpin C, Secq V, Giusiano S et al. A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays. Int. J. Cancer 2009; 124; 2124-2134.
18. Kinsel LB, Szabo E, Greene GL et al. Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res. 1989; 49; 1052-1056.
19. Chen H, Ye D, Xie X, Chen B, Lu W. VEGF, VEGFR expression and activated STATs in ovarian epithelial carcinoma. Gynecol. Oncol. 2004; 94; 630-635.
20. Citores L, Bai L, Sorensen V, Olsnes S. Fibroblast growth factor receptor-induced phosphorylation of STAT1 at the Golgi apparatus without translocation to the nucleus. J. Cell. Physiol. 2007; 212; 148-156.
21. Widschwendter A, Tonko-Gaymayer S, Welte T, Daxenbichler G, Marth C, Doppler W. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin. Cancer Res. 2002; 8; 3065-3074.
22. Battle TE, Frank DA. The role of STATs in apoptosis. Curr. Mol. Med. 2002; 2; 381-392.
23. Nassar A, Lawson D, Cotsonis G, Cohen C. Survivin and caspase-3 expression in breast cancer: correlation with prognostic parameters, proliferation, angiogenesis, and outcome. Appl. Immunohistochem. Mol. Morphol. 2008; 16; 113-120.
24. Lipponen P, Aaltomaa S, Kosma V-M, Syrjänen K. Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur. J. Cancer 1994; 30A; 2068-2073.
25. Vakkala M, Lahteenmaki K, Raunio H, Paakko P, Soini Y. Apoptosis during breast carcinoma progression. Clin. Cancer Res. 1999; 5; 319-324.
26. Bromberg J. Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development. Breast Cancer Res. 2000; 2; 86-90.
27. Kennedy AM, Shogren KL, Zhang M, Turner RT, Spelsberg TC, Maran A. 17β-Estradiol-dependent activation of signal transducer and activator of transcription-1 in human fetal osteoblasts is dependent on Src kinase activity. Endocrinology 2005; 146; 201-207.
28. Song R, Santen R. Membrane initiated estrogen signaling in breast cancer. Biol. Reprod. 2006; 75; 9-16.
29. Axelrod D, Smith J, Kornreich D et al. Breast cancer in young women. J. Am. Coll. Surg. 2008; 206; 1193-1203.
30. Najjar I, Fagard R. STAT1 and pathogens, not a friendly relationship. Biochimie 2010; 92; 425-444.
31. Kovacic B, Stoiber D, Moriggl R et al. STAT1 acts as a tumor promoter for leukemia development. Cancer Cell 2006; 10; 77-87.